Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

October 17, 2024

Study Completion Date

October 17, 2024

Conditions

Breast CancerFilgrastim Adverse Reaction

Interventions

DRUG

Placebo

DRUG

famotidine and loratadine

famotidine 20 mg once daily and loratadine 10 mg once daily

Trial Locations (1)

Mansoura University, Al Mansurah

All Listed Sponsors

lead

Noha Mansour

OTHER

NCT06265077 - Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients | Biotech Hunter | Biotech Hunter